Institutional Ownership
Edwards Lifesciences Corp
CUSIP 28176E108COMEWQ1 2026
Latest EPS (Diluted)
$0.66
Q1 2026 · Mar 31, 2026
Latest Revenue
$1.65B
Reported quarter
Latest Net Income
$380.70M
Reported quarter
Quarters on Record
12
From SEC XBRL filings
Quarterly Earnings
EPS, revenue & net income · SEC XBRL (10-Q / 10-K)
| Period | Quarter | EPS (Basic) | EPS (Diluted) | Revenue | Net Income | Form |
|---|---|---|---|---|---|---|
| Mar 31, 2026 | Q1 2026 | $0.66 | $0.66 | $1.65B | $380.70M | 10-Q |
| Sep 30, 2025 | Q3 2025 | $0.50 | $0.50 | $1.55B | $291.10M | 10-Q |
| Jun 30, 2025 | Q2 2025 | $0.57 | $0.56 | $1.53B | $333.20M | 10-Q |
| Mar 31, 2025 | Q1 2025 | $0.61 | $0.61 | $1.41B | $358.00M | 10-Q |
| Dec 31, 2024 | Q4 2024 | $0.65 | $0.65 | $1.39B | $385.60M | 10-K |
| Sep 30, 2024 | Q3 2024 | $5.14 | $5.13 | $1.35B | $3.07B | 10-Q |
| Jun 30, 2024 | Q2 2024 | $0.61 | $0.61 | $1.37B | $366.30M | 10-Q |
| Mar 31, 2024 | Q1 2024 | $0.58 | $0.58 | $1.33B | $351.90M | 10-Q |
| Dec 31, 2023 | Q4 2023 | $0.61 | $0.61 | $1.27B | $369.90M | 10-K |
| Sep 30, 2023 | Q3 2023 | $0.63 | $0.63 | $1.24B | $384.90M | 10-K |
| Jun 30, 2023 | Q2 2023 | $0.51 | $0.50 | $1.28B | $307.10M | 10-K |
| Mar 31, 2023 | Q1 2023 | $0.56 | $0.56 | $1.22B | $340.50M | 10-K |